Exide Defends 11.7% EBITDA as Lithium-ion Trials Near

Exide Industries Limited — Q4 FY25-26 Earnings Call (May 06, 2026)

1. Overall Tone of Management: Optimistic

• Management highlights “highest-ever quarterly revenue”, double-digit growth across most verticals, and stable EBITDA margin sequentially (“maintain… EBITDA margin of 11.7%”).
• Forward-looking language is generally constructive but tempered: “cautiously optimistic” on lead-acid demand and “watch and monitor” inflation.

2. Key Themes from Management Commentary

• Demand tailwinds from GST 2.0 and macro conditions
• Management attributes strength to GST 2.0 reforms, low inflation/interest rates, and rural revival, especially in 2H FY26.
• Core lead-acid business momentum
• Q4: ~9.4% YoY overall revenue growth, domestic +12.5% YoY, and ~92% of business grew (including domestic ex-telecom).
• Sequentially, they emphasize production ramp-up, capacity utilization, and fixed-cost absorption.
• Margin resilience despite commodity shocks
• Commodity inflation is acknowledged as severe (LPG/sulfuric acid/plastics; rupee depreciation).
• Yet EBITDA margin is defended via manufacturing excellence, tight cost control, and warranty cost reduction.
• Exports and telecom remain structural/tech-shift challenged
• Exports subdued due to geopolitics; management expects uncertainty to persist at least H1 FY27.
• Telecom and E-rickshaw are described as shifting to lithium-ion, contributing to declines.
• “One-Exide” operating model synergy
• Management credits the FY25 shift to One-Exide for agility and customer focus, linking it to improved performance in FY26.
• Lithium-ion project: ramping toward trials and early sample deliveries
• Investment: Rs. 600 cr in Q4, ~Rs. 1,500 cr in FY26, total equity in Exide Energy: Rs. 4,802 cr.
• Cylindrical lines: sample delivery expected “by around this month onwards”; prismatic trials shortly after.
• They position prismatic (LFP) as potentially earlier revenue due to less homologation burden.

3. Q&A Analysis

Theme A: Segment mix, exports/telecom outlook, and overall growth

• Core questions
• Clarify revenue split: telecom/exports as % of topline.
• Whether exports volatility should normalize and enable better topline growth next year.
• Medium-term growth potential for “core business.”
• Management response
• Telecom/exports decline quantified: exports ~5%, telecom ~3% (with telecom including some E-rickshaw).
• Exports: expects baseline is low after decline and sees “substantial upside” if geopolitical tensions ease; exports previously ~8%.
• Core growth potential: “high single-digit to early-double digit growth” for core business; overall core growth possible even with telecom decline.
• Notable/partial or strong points
• Strong confidence on growth range, but no hard quantitative FY27 guidance; relies on qualitative “chance” and “baseline is low.”

Theme B: Commodity inflation, pass-through, and pricing actions

• Core questions
• Magnitude of commodity impact in Q4 and expected escalation into Q1 FY27.
• How much price hike taken (trade/aftermarket) and whether further hikes are needed.
• OEM contract lag and what’s covered.
• Bill-of-material exposure to key commodities (lead/acid/plastics/sulfur, etc.).
• Management response
• Q4 commodity impact: ~Rs. 150 cr negative impact; gross margin down ~90 bps (Q3 31.6% → Q4 30.1%).
• EBITDA held sequentially at 11.7% via cost controls and warranty reduction.
• Price hikes: multiple tranches ~5–6% total across businesses; April 1st ~3%; last round 1 April plus another in April.
• Further hikes: difficult to comment, but April exit prices much higher than March (example sulfuric acid: 58/kg → 74/kg, “5x” vs a year ago). “We will have to take the price hikes. We have no other option.”
• OEM lag: management says “I will rather say it’s a quarter.”
• BOM exposure: lead/acid/plastics are 95–96% of BOM; they refuse exact % breakdown (“not in public domain”).
• Sulfuric acid/sulfur: clarified sulfur price spike (not acid) and timing; sequential jump in Q4 and April exit higher.
• Evasive/partial
• Refuses detailed BOM % exposure and FY27 “how much price increase required” quantification.
• Commodity escalation into Q1 is discussed qualitatively; no explicit FY27 margin sensitivity.

Theme C: Lithium-ion: capex, timelines, revenue start, pricing, yields

• Core questions
• Additional investment needed in FY27/FY28; total capex outlook.
• When cell revenue starts vs pack revenue; status of trials and sample deliveries.
• Pricing vs imported cells (parity/premium) and learning curve (yields).
• Government support/subsidies and policy status.
• Management response
• FY27 investment: Board approval for Rs. 1,400 cr in FY27 (mix of capex + opex + working capital).
• Revenue timing:
  • They correct that cell supplies not started; process validation completed.
  • Cylindrical sample supplies: end of this month or next month.
  • Prismatic samples: targeting June–July for customer validation.
  • They emphasize official start date will be disclosed.
• Yields/pricing:
  • Yield target: “best yield level should be 90%.”
  • Pricing target: meet landed cost of imported cell via >85% utilization, 90% yield, and localization; also cites China VAT changes (imported cells costlier).
• Learning curve: yield improves with three-shift/continuous running, but exact time-to-yield is not committed.
• Evasive/partial
• No explicit ROCE/margin targets for lithium-ion; management repeatedly defers (“not proper… depends on commodity prices when commercialize”).
• Pricing “parity” is framed as a target, not a guarantee.

Theme D: Industrial/data center opportunity and lithium substitution risk

• Core questions
• Current revenue share from industrial infra segments (data centers, railways, motive power, etc.).
• Whether industrial customers will shift to lithium-ion later (risk to lead-acid).
• Management response
• Industrial infra (ex-telecom) ~30% of revenue; data center revenue in quarter ~Rs. 75–100 cr.
• Data centers: mix of lead-acid and lithium-ion; lead-acid still relevant where redundancy/footprint requirements differ.
• They cite product differentiation: front-access high-power batteries for data centers.
• BESS expected to be more lithium-ion; they’re developing LFP prismatic for stationary storage.
• Strong point
• Clear segmentation of where lithium is likely to win (BESS) vs where lead-acid remains relevant (certain data center tiers).

4. Guidance / Outlook

Explicit guidance (quantitative)

• EBITDA margin (sequential): maintained at 11.7% in Q4.
• Price hikes already taken: ~5–6% across businesses; April 1st ~3%; additional April correction.
• Exports uncertainty: expected to remain “at least in the first half of this current year” (FY27).
• Lithium-ion capex/investment:
• FY26: Rs. 1,500 cr (plus Rs. 600 cr in Q4).
• FY27: Rs. 1,400 cr (board-approved; capex + opex + working capital).
• Lithium-ion trials/revenue timing:
• Cylindrical sample delivery: “by around this month onwards” (and “end of this month or next month”).
• Prismatic customer validation samples: June–July.
• Yield target: 90% (best yield level).
• Utilization target (for pricing parity logic): >85% utilization.

Implicit signals (qualitative)

• Lead-acid demand outlook: “positive across most business” but “cautiously optimistic” due to inflation risk.
• Core growth: management believes high-single-digit to early-double-digit growth is possible for core business.
• Exports upside: “good chance to increase our share of Exports” if geopolitical tensions ease.
• Commodity pass-through: management signals continued price corrections are likely given April exit commodity levels and “no other option.”

5. Standout Statements (directly revealing)

• Commodity pass-through stance (strong):
• “We will have to take the price hikes. We have no other option.”
• Exports uncertainty window:
• “We expect these uncertainties to remain for at least in the first half of this current year.”
• Core growth confidence (range):
• “high-single to double-digit growth for the overall core business is possible.”
• Lithium-ion revenue sequencing:
• “possibly the revenue stream will come first from the prismatic lines” (LFP) due to faster validation/homologation.
• Pricing parity target for lithium-ion:
• “our target will be meeting the landed cost of the imported cell.”
• OEM contract lag:
• “I will rather say it’s a quarter.”
• Lithium-ion yield target:
• “The best yield level should be 90%.”
• Government support “scale” condition (policy realism):
• “unless there is about 20–25 gigawatt of capacity in India… that is a minimum base where we will get a lot of support”

6. Red Flags / Positive Signals

Red flags
– No quantitative FY27 margin guidance despite heavy commodity discussion; lithium-ion ROCE/margins also deferred.
– BOM exposure transparency limited: refuses exact % exposure and FY27 “required price increase” math.
– Exports recovery depends on geopolitics: “expect uncertainties… at least H1” and “chance” language.
– Lithium-ion revenue timing still probabilistic: sample delivery windows given, but revenue recognition depends on customer validation.

Positive signals
– Demonstrated margin resilience: EBITDA margin held sequentially at 11.7% despite gross margin compression.
– Clear operational levers: capacity ramp-up, cost control, warranty cost reduction.
– Lithium-ion readiness progress: process validation completed; sample delivery scheduled; capex plan approved for FY27.
– Pricing discipline: multiple tranches of price increases already executed; OEM negotiations ongoing.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current (Q4 FY26): more confident/constructive—“highest-ever quarterly revenue,” margin stability, and clearer lithium-ion trial milestones.
• Prior (Q3 FY26, Feb 03 2026): also optimistic but more defensive on commodity pressure; still emphasized cost excellence and margin support.
• Prior (Q2 FY26, Nov 17 2025): more cautious due to GST 2.0 destocking and production cuts; emphasized cash management and “stop price correction” to pass GST benefit.
• Shift classification: More Optimistic than Q2; slightly more confident than Q3 due to stronger Q4 performance and clearer lithium-ion sample timelines.

b. Tracking Past Commitments vs Outcomes

• GST 2.0 demand rebound expectation
• Past narrative (Q2 FY26): expected rebound in Q3 after GST cuts; production cuts were temporary for cash/inventory.
• Outcome (Q4 FY26): management reports GST-led demand surge continued; Q4 had strong growth and “highest-ever quarterly revenue.”
• ✅ Delivered
• Lithium-ion commissioning / trial readiness
• Past (Q2 FY26): expected start production toward end of FY26, process validation and sample prep ongoing.
• Current (Q4 FY26): process validation completed; sample supplies expected end of month/next month; prismatic trials June–July.
• ✅ Delivered / On track
• Margin trajectory improvement
• Past (Q2 FY26): margin pressured; management focused on cost excellence and cash.
• Current: gross margin down but EBITDA held at 11.7%; implies cost actions working.
• ✅ Partially delivered (EBITDA resilience, but no return to older “13.5–14%” explicitly stated in Q4 call)

c. Narrative Shifts

• Exports/telecom framing becomes more time-bound
• Q2/Q3: exports impacted by tariffs/geopolitics; “work in progress.”
• Q4: explicitly states uncertainty likely persists at least H1 FY27, but also frames a recovery upside if tensions ease.
• Lithium-ion story shifts from “project readiness” to “customer validation and revenue sequencing”
• Earlier calls: commissioning/trials and general margin expectations.
• Current: specific sample delivery windows and yield/pricing targets.
• Commodity discussion becomes more granular
• Q4 includes specific Rs. 150 cr impact and gross margin bps movement; still with limited BOM % disclosure.

d. Consistency & Credibility Signals

• Credibility: Medium-High
• Consistent themes: cost excellence, price pass-through, and cautious optimism on demand.
• Lithium-ion timelines have moved from “FY26 production” to “sample delivery by this month/next month,” which appears consistent with earlier “trial production” framing.
• However, management continues to avoid hard margin/ROCE guidance for lithium-ion and refuses detailed BOM exposure, limiting verifiability.

e. Evolution of Key Themes

• Demand: Improving/stable (GST-driven strength in Q4; rural revival).
• Margins: Stable EBITDA despite gross margin compression; cost control working.
• Exports: Deteriorated vs earlier (share down), but management now provides a clearer recovery narrative.
• Lithium-ion: Improving from “commissioning” to “validation and pricing/yield targets.”

f. Additional Insights (cross-period intelligence)

• Price pass-through has accelerated over time
• Q2: management stopped price correction to pass GST benefit.
• Q3/Q4: they resumed and executed multiple tranches (Jan/Mar/20 Mar/1 Apr + April), suggesting commodity inflation became harder to absorb.
• Lithium-ion risk is being reframed from “uncertainty” to “indexed/derisked”
• Q4 emphasizes pricing parity via landed cost logic and indexing (similar to lead formula approach), but still avoids committing to final profitability.